Tesamorelin 10mg research peptide UK is the advanced-format full-length 44-amino acid GHRH analogue for established UK laboratory programmes requiring multi-arm or longitudinal GHRH receptor engagement studies. ≥98% purity. Janoshik tested. Same-day UK dispatch. Research use only.
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
TESAMORELIN 10mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only
Tesamorelin 10mg:
https://verify.janoshik.com/tests/125394-Tesamorelin_10mg_Z9R5QHGVYJ8S
Research use only • UK dispatch • Orders before 4pm ship same day • Secure checkout
Tesamorelin 10mg Research Peptide UK
Tesamorelin 10mg is the advanced-format version of the only full-length GHRH research analogue in the Ascend Peptides UK range. Identical compound to the 5mg format — C221H366N72O67S, approximately 5,135.94 Da, N-terminal trans-3-hexenoic acid modification — but providing the research capacity for full dose-response gradients, multi-arm GHRH analogue comparisons, and extended single-batch longitudinal investigations that the 5mg format cannot support.
The tesamorelin 10mg research peptide format is appropriate when the pilot phase has validated the experimental design using the 5mg format, and the full research programme now requires consistent compound conditions across multiple time points or treatment arms. Single-batch supply across extended longitudinal studies is particularly important where batch-to-batch molecular variability would introduce systematic error into time-series data. For first-time tesamorelin research and full mechanism detail, see the buy tesamorelin 5mg research guide and the tesamorelin 10mg research guide on the Ascend Peptides UK blog.
Tesamorelin 10mg is particularly suited to multi-analogue GHRH comparison studies run at the scale that parallel arms require. The complete three-analogue comparison — Tesamorelin 10mg (full-length 44 AA), CJC-1295 Without DAC 10mg (modified 29 AA, DPP-IV resistant), and Sermorelin 2mg (native 29 AA, shortest half-life at approximately 12 minutes) — provides a comprehensive GHRH structural toolkit. These three compounds differ in sequence length, receptor contact surface, DPP-IV resistance, and in vitro half-life, allowing comparative evaluation of sequence length, receptor interaction surface, enzymatic stability, and signalling-duration characteristics within experimental models.
For GHRP complement in combined pulsatile GH protocols alongside tesamorelin, Ipamorelin 10mg provides the GHS-R1a pathway activation that is mechanistically distinct from GHRHR activation. For downstream IGF-1 axis research alongside GH axis stimulation studies, IGF-1 LR3 1mg provides the growth factor research tool.
All tesamorelin 10mg batches are independently tested by Janoshik. HPLC purity confirmed at greater than or equal to 98%. LC-MS confirms the full-length structure, including N-terminal modification.
For laboratory handling purposes, the lyophilised material may be reconstituted using bacteriostatic water or another suitable buffered aqueous solution, depending on analytical protocol requirements. Store lyophilised material at -20°C and avoid repeated freeze-thaw cycles.
WADA Status: Prohibited at all times.
DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.
A curated entry point for buyers comparing quality, documentation, and availability.
UK same-day dispatch – PCI-
compliant payments –
Laboratory research only
© 2026 by Ascend Peptides Uk.
